<?xml version='1.0' encoding='utf-8'?>
<document id="27151461"><sentence text="Pharmacokinetics of mangiferin and its metabolite-norathyriol, Part 2: Influence of UGT, CYP450, P-gp, and enterobacteria and the potential interaction in Rhizoma Anemarrhenae decoction with timosaponin B2 as the major contributor."><entity charOffset="20-30" id="DDI-PubMed.27151461.s1.e0" text="mangiferin" /><entity charOffset="191-205" id="DDI-PubMed.27151461.s1.e1" text="timosaponin B2" /><pair ddi="false" e1="DDI-PubMed.27151461.s1.e0" e2="DDI-PubMed.27151461.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s1.e0" e2="DDI-PubMed.27151461.s1.e1" /></sentence><sentence text="The poor bioavailability of mangiferin (MGF) is a major obstacle on its further development"><entity charOffset="28-38" id="DDI-PubMed.27151461.s2.e0" text="mangiferin" /><entity charOffset="40-43" id="DDI-PubMed.27151461.s2.e1" text="MGF" /><pair ddi="false" e1="DDI-PubMed.27151461.s2.e0" e2="DDI-PubMed.27151461.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s2.e0" e2="DDI-PubMed.27151461.s2.e1" /></sentence><sentence text=" Aimed to illustrate the underlying mechanism and improve its poor exposure, the compared PK profiles of MGF and norathyriol (NTR) after different MGF preparation were performed: pure MGF, the Rhizoma Anemarrhenae (Zhi-mu) decoction, MGF, and timosaponin B2 (TB-2) combination"><entity charOffset="113-124" id="DDI-PubMed.27151461.s3.e0" text="norathyriol" /><entity charOffset="243-257" id="DDI-PubMed.27151461.s3.e1" text="timosaponin B2" /><entity charOffset="105-118" id="DDI-PubMed.27151461.s3.e2" text="MGF" /><entity charOffset="147-160" id="DDI-PubMed.27151461.s3.e3" text="MGF" /><entity charOffset="184-197" id="DDI-PubMed.27151461.s3.e4" text="MGF" /><entity charOffset="234-247" id="DDI-PubMed.27151461.s3.e5" text="MGF" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e2" e2="DDI-PubMed.27151461.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e0" e2="DDI-PubMed.27151461.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e0" e2="DDI-PubMed.27151461.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e0" e2="DDI-PubMed.27151461.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e0" e2="DDI-PubMed.27151461.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e0" e2="DDI-PubMed.27151461.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e3" e2="DDI-PubMed.27151461.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e3" e2="DDI-PubMed.27151461.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e3" e2="DDI-PubMed.27151461.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e3" e2="DDI-PubMed.27151461.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e4" e2="DDI-PubMed.27151461.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e4" e2="DDI-PubMed.27151461.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e4" e2="DDI-PubMed.27151461.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e5" e2="DDI-PubMed.27151461.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27151461.s3.e5" e2="DDI-PubMed.27151461.s3.e1" /></sentence><sentence text=" Furthermore, the potential contributing factors, including uridine diphosphoglucuronosyltransferase (UGT), cytochrome P450 (CYP450), P-gp, and enterobacterial were investigated by comparing the PK profiles with and without the corresponding inhibitors or in different rat models"><entity charOffset="60-67" id="DDI-PubMed.27151461.s4.e0" text="uridine" /></sentence><sentence text=" After taking MGF, CYP450 and UGT inhibition could decrease MGF and NTR exposure; P-gp inhibition slightly enhanced (48%) MGF exposure, whereas more apparent for the improved NTR exposure (302%); enterobacterial inhibition almost completely stopped the NTR production, but no such effect was observed for MGF"><entity charOffset="14-20" id="DDI-PubMed.27151461.s5.e0" text="MGF" /><entity charOffset="60-66" id="DDI-PubMed.27151461.s5.e1" text="MGF" /><entity charOffset="122-128" id="DDI-PubMed.27151461.s5.e2" text="MGF" /><entity charOffset="305-311" id="DDI-PubMed.27151461.s5.e3" text="MGF" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e0" e2="DDI-PubMed.27151461.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e0" e2="DDI-PubMed.27151461.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e0" e2="DDI-PubMed.27151461.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e0" e2="DDI-PubMed.27151461.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e1" e2="DDI-PubMed.27151461.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e1" e2="DDI-PubMed.27151461.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e1" e2="DDI-PubMed.27151461.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e2" e2="DDI-PubMed.27151461.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s5.e2" e2="DDI-PubMed.27151461.s5.e3" /></sentence><sentence text=" Compared with the limited improvement by the abovementioned inhibition, the MGF and NTR exposure could significantly increase by 11"><entity charOffset="77-79" id="DDI-PubMed.27151461.s6.e0" text="MGF" /></sentence><sentence text="5- and 5" /><sentence text="9-fold in the Zhi-mu decoction compared with the MGF treatment, probably contributed to TB-2 as an absorption enhancer because the MGF and TB-2 combination produced a similar level of improvement on the PK paremeters of MGF and NTR to the herb treatment"><entity charOffset="49-51" id="DDI-PubMed.27151461.s8.e0" text="MGF" /><entity charOffset="131-133" id="DDI-PubMed.27151461.s8.e1" text="MGF" /><entity charOffset="220-222" id="DDI-PubMed.27151461.s8.e2" text="MGF" /><pair ddi="false" e1="DDI-PubMed.27151461.s8.e0" e2="DDI-PubMed.27151461.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s8.e0" e2="DDI-PubMed.27151461.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s8.e0" e2="DDI-PubMed.27151461.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s8.e1" e2="DDI-PubMed.27151461.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s8.e1" e2="DDI-PubMed.27151461.s8.e2" /></sentence><sentence text=" Likewise, most of the effects by UGT, CYP450, P-gp, and enterobacteria followed a similar variation tendency between them" /><sentence text=" Therefore, the poor bioavailability of MGF possibly mainly attributed to its poor membrane permeability, but not transporters or metabolic enzymes, and the compatibility of MGF and TB-2 could probably expand the prospective application of MGF by improving its bioavailability"><entity charOffset="40-42" id="DDI-PubMed.27151461.s10.e0" text="MGF" /><entity charOffset="174-176" id="DDI-PubMed.27151461.s10.e1" text="MGF" /><entity charOffset="240-242" id="DDI-PubMed.27151461.s10.e2" text="MGF" /><pair ddi="false" e1="DDI-PubMed.27151461.s10.e0" e2="DDI-PubMed.27151461.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27151461.s10.e0" e2="DDI-PubMed.27151461.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s10.e0" e2="DDI-PubMed.27151461.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27151461.s10.e1" e2="DDI-PubMed.27151461.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27151461.s10.e1" e2="DDI-PubMed.27151461.s10.e2" /></sentence><sentence text=" Â© 2016 BioFactors, 42(5):545-555, 2016" /><sentence text="" /></document>